In late July, VUMC will begin recruiting volunteers for a study of an experimental vaccine developed by Moderna Inc. in collaboration with the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.
The placebo-controlled trial, open to individuals age 18 years and older, is to study how effective the vaccine is in protecting against COVID-19 and how long protection lasts, according to a news release.
“Vaccine development around COVID-19 is moving at an unprecedented pace due to the remarkable partnerships between academic institutions, the NIH and pharmaceutical industry leaders,” said Buddy Creech, principal investigator of the NIH-funded Vanderbilt Vaccine and Treatment Evaluation Unit, in the release. “We are pressing full speed ahead to provide an answer to this pandemic, while also taking the necessary steps to ensure that new vaccines and therapeutic drugs are both safe and effective.”
Officials said VUMC is one of several U.S. centers participating in the nationwide trial, which will enroll 30,000 volunteers over the next two months.